New pathogenic and therapeutic paradigms in atopic dermatitis

• Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targete...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Malajian, Dana [verfasserIn] Guttman-Yassky, Emma

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2015

Schlagwörter:	FLG IgE DEFB1 EASI IFN-γ Th IDEC TLR SCORAD NOD AD AMP TSLP PDE4 ADSI SPINK5 iDC CCL PBMC LOR IL-4R CsA K16 CCR LC TMEM79 NB-UVB FcεRI CTRH2 IVL DC

Umfang:	8

Übergeordnetes Werk:	Enthalten in: The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types - McLaughlin, Richard J. ELSEVIER, 2022, the official journal of the International Cytokine Society, Oxford [u.a.]
Übergeordnetes Werk:	volume:73 ; year:2015 ; number:2 ; pages:311-318 ; extent:8

Links:	Volltext

DOI / URN:	10.1016/j.cyto.2014.11.023

Katalog-ID:	ELV018710115

Internformat


LEADER	01000caa a22002652 4500
001	ELV018710115
003	DE-627
005	20230623144323.0
007	cr uuu---uuuuu
008	180602s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.cyto.2014.11.023 \|2 doi
028	5	2	\|a GBVA2015017000008.pica
035			\|a (DE-627)ELV018710115
035			\|a (ELSEVIER)S1043-4666(14)00606-1
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 570
082	0	4	\|a 570 \|q DE-600
082	0	4	\|a 610 \|q VZ
084			\|a 44.83 \|2 bkl
100	1		\|a Malajian, Dana \|e verfasserin \|4 aut
245	1	0	\|a New pathogenic and therapeutic paradigms in atopic dermatitis
264		1	\|c 2015
300			\|a 8
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a • Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD.
650		7	\|a FLG \|2 Elsevier
650		7	\|a IgE \|2 Elsevier
650		7	\|a DEFB1 \|2 Elsevier
650		7	\|a EASI \|2 Elsevier
650		7	\|a IFN-γ \|2 Elsevier
650		7	\|a Th \|2 Elsevier
650		7	\|a IDEC \|2 Elsevier
650		7	\|a TLR \|2 Elsevier
650		7	\|a SCORAD \|2 Elsevier
650		7	\|a NOD \|2 Elsevier
650		7	\|a AD \|2 Elsevier
650		7	\|a AMP \|2 Elsevier
650		7	\|a TSLP \|2 Elsevier
650		7	\|a PDE4 \|2 Elsevier
650		7	\|a ADSI \|2 Elsevier
650		7	\|a SPINK5 \|2 Elsevier
650		7	\|a iDC \|2 Elsevier
650		7	\|a CCL \|2 Elsevier
650		7	\|a PBMC \|2 Elsevier
650		7	\|a LOR \|2 Elsevier
650		7	\|a IL-4R \|2 Elsevier
650		7	\|a CsA \|2 Elsevier
650		7	\|a K16 \|2 Elsevier
650		7	\|a CCR \|2 Elsevier
650		7	\|a LC \|2 Elsevier
650		7	\|a TMEM79 \|2 Elsevier
650		7	\|a NB-UVB \|2 Elsevier
650		7	\|a FcεRI \|2 Elsevier
650		7	\|a CTRH2 \|2 Elsevier
650		7	\|a IVL \|2 Elsevier
650		7	\|a DC \|2 Elsevier
700	1		\|a Guttman-Yassky, Emma \|4 oth
773	0	8	\|i Enthalten in \|n Elsevier \|a McLaughlin, Richard J. ELSEVIER \|t The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types \|d 2022 \|d the official journal of the International Cytokine Society \|g Oxford [u.a.] \|w (DE-627)ELV008219540
773	1	8	\|g volume:73 \|g year:2015 \|g number:2 \|g pages:311-318 \|g extent:8
856	4	0	\|u https://doi.org/10.1016/j.cyto.2014.11.023 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a SSG-OLC-PHA
936	b	k	\|a 44.83 \|j Rheumatologie \|j Orthopädie \|q VZ
951			\|a AR
952			\|d 73 \|j 2015 \|e 2 \|h 311-318 \|g 8
953			\|2 045F \|a 570

Indexfelder

author_variant	d m dm
matchkey_str	malajiandanaguttmanyasskyemma:2015----:eptoeiadhrpuiprdgsn
hierarchy_sort_str	2015
bklnumber	44.83
publishDate	2015
allfields	10.1016/j.cyto.2014.11.023 doi GBVA2015017000008.pica (DE-627)ELV018710115 (ELSEVIER)S1043-4666(14)00606-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Malajian, Dana verfasserin aut New pathogenic and therapeutic paradigms in atopic dermatitis 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD. FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC Elsevier Guttman-Yassky, Emma oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:73 year:2015 number:2 pages:311-318 extent:8 https://doi.org/10.1016/j.cyto.2014.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 73 2015 2 311-318 8 045F 570
spelling	10.1016/j.cyto.2014.11.023 doi GBVA2015017000008.pica (DE-627)ELV018710115 (ELSEVIER)S1043-4666(14)00606-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Malajian, Dana verfasserin aut New pathogenic and therapeutic paradigms in atopic dermatitis 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD. FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC Elsevier Guttman-Yassky, Emma oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:73 year:2015 number:2 pages:311-318 extent:8 https://doi.org/10.1016/j.cyto.2014.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 73 2015 2 311-318 8 045F 570
allfields_unstemmed	10.1016/j.cyto.2014.11.023 doi GBVA2015017000008.pica (DE-627)ELV018710115 (ELSEVIER)S1043-4666(14)00606-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Malajian, Dana verfasserin aut New pathogenic and therapeutic paradigms in atopic dermatitis 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD. FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC Elsevier Guttman-Yassky, Emma oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:73 year:2015 number:2 pages:311-318 extent:8 https://doi.org/10.1016/j.cyto.2014.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 73 2015 2 311-318 8 045F 570
allfieldsGer	10.1016/j.cyto.2014.11.023 doi GBVA2015017000008.pica (DE-627)ELV018710115 (ELSEVIER)S1043-4666(14)00606-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Malajian, Dana verfasserin aut New pathogenic and therapeutic paradigms in atopic dermatitis 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD. FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC Elsevier Guttman-Yassky, Emma oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:73 year:2015 number:2 pages:311-318 extent:8 https://doi.org/10.1016/j.cyto.2014.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 73 2015 2 311-318 8 045F 570
allfieldsSound	10.1016/j.cyto.2014.11.023 doi GBVA2015017000008.pica (DE-627)ELV018710115 (ELSEVIER)S1043-4666(14)00606-1 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Malajian, Dana verfasserin aut New pathogenic and therapeutic paradigms in atopic dermatitis 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD. FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC Elsevier Guttman-Yassky, Emma oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:73 year:2015 number:2 pages:311-318 extent:8 https://doi.org/10.1016/j.cyto.2014.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 73 2015 2 311-318 8 045F 570
language	English
source	Enthalten in The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types Oxford [u.a.] volume:73 year:2015 number:2 pages:311-318 extent:8
sourceStr	Enthalten in The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types Oxford [u.a.] volume:73 year:2015 number:2 pages:311-318 extent:8
format_phy_str_mv	Article
bklname	Rheumatologie Orthopädie
institution	findex.gbv.de
topic_facet	FLG IgE DEFB1 EASI IFN-γ Th IDEC TLR SCORAD NOD AD AMP TSLP PDE4 ADSI SPINK5 iDC CCL PBMC LOR IL-4R CsA K16 CCR LC TMEM79 NB-UVB FcεRI CTRH2 IVL DC
dewey-raw	570
isfreeaccess_bool	false
container_title	The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types
authorswithroles_txt_mv	Malajian, Dana @@aut@@ Guttman-Yassky, Emma @@oth@@
publishDateDaySort_date	2015-01-01T00:00:00Z
hierarchy_top_id	ELV008219540
dewey-sort	3570
id	ELV018710115
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV018710115</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623144323.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cyto.2014.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015017000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV018710115</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-4666(14)00606-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malajian, Dana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New pathogenic and therapeutic paradigms in atopic dermatitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FLG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DEFB1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EASI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IFN-γ</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Th</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IDEC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TLR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SCORAD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NOD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AMP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TSLP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PDE4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ADSI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SPINK5</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">iDC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PBMC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL-4R</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CsA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">K16</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TMEM79</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NB-UVB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FcεRI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTRH2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IVL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guttman-Yassky, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">McLaughlin, Richard J. ELSEVIER</subfield><subfield code="t">The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the International Cytokine Society</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV008219540</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:311-318</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cyto.2014.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="j">Rheumatologie</subfield><subfield code="j">Orthopädie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">311-318</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
author	Malajian, Dana
spellingShingle	Malajian, Dana ddc 570 ddc 610 bkl 44.83 Elsevier FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC New pathogenic and therapeutic paradigms in atopic dermatitis
authorStr	Malajian, Dana
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV008219540
format	electronic Article
dewey-ones	570 - Life sciences; biology 610 - Medicine & health
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	570 570 DE-600 610 VZ 44.83 bkl New pathogenic and therapeutic paradigms in atopic dermatitis FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC Elsevier
topic	ddc 570 ddc 610 bkl 44.83 Elsevier FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC
topic_unstemmed	ddc 570 ddc 610 bkl 44.83 Elsevier FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC
topic_browse	ddc 570 ddc 610 bkl 44.83 Elsevier FLG Elsevier IgE Elsevier DEFB1 Elsevier EASI Elsevier IFN-γ Elsevier Th Elsevier IDEC Elsevier TLR Elsevier SCORAD Elsevier NOD Elsevier AD Elsevier AMP Elsevier TSLP Elsevier PDE4 Elsevier ADSI Elsevier SPINK5 Elsevier iDC Elsevier CCL Elsevier PBMC Elsevier LOR Elsevier IL-4R Elsevier CsA Elsevier K16 Elsevier CCR Elsevier LC Elsevier TMEM79 Elsevier NB-UVB Elsevier FcεRI Elsevier CTRH2 Elsevier IVL Elsevier DC
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	e g y egy
hierarchy_parent_title	The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types
hierarchy_parent_id	ELV008219540
dewey-tens	570 - Life sciences; biology 610 - Medicine & health
hierarchy_top_title	The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV008219540
title	New pathogenic and therapeutic paradigms in atopic dermatitis
ctrlnum	(DE-627)ELV018710115 (ELSEVIER)S1043-4666(14)00606-1
title_full	New pathogenic and therapeutic paradigms in atopic dermatitis
author_sort	Malajian, Dana
journal	The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types
journalStr	The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types
lang_code	eng
isOA_bool	false
dewey-hundreds	500 - Science 600 - Technology
recordtype	marc
publishDateSort	2015
contenttype_str_mv	zzz
container_start_page	311
author_browse	Malajian, Dana
container_volume	73
physical	8
class	570 570 DE-600 610 VZ 44.83 bkl
format_se	Elektronische Aufsätze
author-letter	Malajian, Dana
doi_str_mv	10.1016/j.cyto.2014.11.023
dewey-full	570 610
title_sort	new pathogenic and therapeutic paradigms in atopic dermatitis
title_auth	New pathogenic and therapeutic paradigms in atopic dermatitis
abstract	• Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD.
abstractGer	• Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD.
abstract_unstemmed	• Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA
container_issue	2
title_short	New pathogenic and therapeutic paradigms in atopic dermatitis
url	https://doi.org/10.1016/j.cyto.2014.11.023
remote_bool	true
author2	Guttman-Yassky, Emma
author2Str	Guttman-Yassky, Emma
ppnlink	ELV008219540
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth
doi_str	10.1016/j.cyto.2014.11.023
up_date	2024-07-06T19:30:49.123Z
_version_	1803859262570496000
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV018710115</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623144323.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cyto.2014.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015017000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV018710115</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-4666(14)00606-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malajian, Dana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New pathogenic and therapeutic paradigms in atopic dermatitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Atopic Dermatitis (AD) is an increasingly prevalent inflammatory skin disease. • Atopic dermatitis is a Th2- and Th22-polarized disease. • There is a large, unmet need for effective therapeutics for AD. • Translational research is leading pathogenic and therapeutic transformations in AD. • Targeted immune antagonists show promise in ameliorating the disease in severe AD.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FLG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DEFB1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EASI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IFN-γ</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Th</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IDEC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TLR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SCORAD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NOD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AMP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TSLP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PDE4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ADSI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SPINK5</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">iDC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PBMC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IL-4R</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CsA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">K16</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CCR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TMEM79</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NB-UVB</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FcεRI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTRH2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IVL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guttman-Yassky, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">McLaughlin, Richard J. ELSEVIER</subfield><subfield code="t">The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the International Cytokine Society</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV008219540</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:311-318</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cyto.2014.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="j">Rheumatologie</subfield><subfield code="j">Orthopädie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">311-318</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
score	7.3973236

Nicht das Richtige dabei?

Schreiben Sie uns!

New pathogenic and therapeutic paradigms in atopic dermatitis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?